CYP
Director Trades
| Date | Director | Value |
|---|
Company News
Cynata Enters Countdown to Landmark Clinical Results as World-First MSC Platform Advances
Mesenchymal stromal cells (MSCs) have long been regarded as one of nature’s most powerful repair systems—cells with the ability to reduce inflammation, regulate immune responses and stimulate tissue healing. For decades, they have been seen as a potential foundation for an entirely new class of medicine. Cynata Therapeutics (ASX: CYP) is a Melbourne-based biotech advancing […]
ASX biotech stocks benefiting from the COVID-19 story
Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks across the drug, diagnostics and device sectors. Naturally, the biotechs drawing a connection with fighting or detecting the virus – spurious or otherwise – have seen their valuations soar. Not that investor interest is […]
Cynata Therapeutics gets approval for clinical trial on COVID-19
Biotechnology company Cynata Therapeutics (ASX: CYP) intends to develop a treatment for COVID-19 by repurposing its Cymerus mesenchymal stem cells (MSCs) products and research. In a statement to the market, Cynata said it had received ethics committee approval to commence a clinical trial in Australia to investigate early efficacy of Cymerus MSCs in adults admitted […]
Cynata Therapeutics’ stem cells could potentially help treat severe COVID-19 symptoms
Cynata Therapeutics (ASX: CYP) revealed it is in “active discussions” with international pharmaceutical companies and other parties regarding using its Cymerus mesenchymal stem cell (MSC) platform to treat COVID-19 patients that develop severe symptoms. According to Cynata, COVID-19 has caused serious ongoing issues including acute respiratory distress syndrome, sepsis and cytokine release syndrome. The company […]
Cynata Therapeutics has positive pre-clinical results using Cymerus stem cell platform to treat sepsis
Pre-clinical studies using Cynata Therapeutics’ (ASX: CYP) Cymerus mesenchymal stem cells in a sepsis model have achieved positive results. In a pre-clinical model of severe pneumonia-induced sepsis, Cynata’s Cymerus treatment had several positive effects including increasing blood oxygen levels and lung compliance, while decreasing inflammation and potential harm to lungs. Alveolar neutrophil infiltration can lead […]
Fujifilm to commercialise Cynata Therapeutics’ mesenchymal stem cell technology
Following a successful phase one clinical trial, FUJIFILM Corporation (Fujifilm) has exercised its option to commercialise Cynata Therapeutics’ (ASX: CYP) mesenchymal stem cell product which can treat and prevent graft-versus-host disease in people. Under the licencing deal, Cynata will receive an upfront fee payment of US$3 million from Fujifilm. Upon reaching future milestones, Fujifilm will […]
Cynata Therapeutics reveals more positive pre-clinical cancer trial results
Biotechnology company Cynata Therapeutics (ASX: CYP) has published encouraging results from its ongoing preclinical program using its proprietary Cymerus platform. The company said it was able to successfully develop genetically engineered mesenchymal stem cells (MSCs) using the Cymerus platform that could establish a means of expressing diagnostic and therapeutic anti-cancer agents. Also, its engineered cells […]
Cynata Therapeutics looks to advance Cymerus stem cell treatment into phase 2 trials
Stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has said that it has “met all clinical endpoints” in its phase 1 trial of flagship drug CYP-001 – for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). The milestone paves the way for Cynata’s proprietary Cymerus technology to enter phase 2 trials for the […]
Cynata study shows positive link between stem cells and cardiac function post-heart attack
Stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has announced positive efficacy data from a study of its Cymerus mesenchymal stem cells (MSCs) in a pre-clinical heart attack model. Specifically, MSC treatment was shown to improve the recovery of cardiac functioning after a heart attack and reduce left ventricular end-systolic diameter (LVESD), compared […]
Phase 2 bone marrow transplant drug trial on the horizon for Cynata Therapeutics
Australian stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) may advance to a phase 2 clinical trial of a new stem cell drug if results of an initial two-stage trial continue to prove the drug’s safety and efficacy. The company has reported positive results on day 28 of the second stage of a […]